Abo Bibliothek: Guest
Critical Reviews™ in Therapeutic Drug Carrier Systems

Erscheint 6 Ausgaben pro Jahr

ISSN Druckformat: 0743-4863

ISSN Online: 2162-660X

The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) IF: 2.7 To calculate the five year Impact Factor, citations are counted in 2017 to the previous five years and divided by the source items published in the previous five years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) 5-Year IF: 3.6 The Immediacy Index is the average number of times an article is cited in the year it is published. The journal Immediacy Index indicates how quickly articles in a journal are cited. Immediacy Index: 0.8 The Eigenfactor score, developed by Jevin West and Carl Bergstrom at the University of Washington, is a rating of the total importance of a scientific journal. Journals are rated according to the number of incoming citations, with citations from highly ranked journals weighted to make a larger contribution to the eigenfactor than those from poorly ranked journals. Eigenfactor: 0.00023 The Journal Citation Indicator (JCI) is a single measurement of the field-normalized citation impact of journals in the Web of Science Core Collection across disciplines. The key words here are that the metric is normalized and cross-disciplinary. JCI: 0.39 SJR: 0.42 SNIP: 0.89 CiteScore™:: 5.5 H-Index: 79

Indexed in

Potential Approaches for Drug Delivery to the Brain: Past, Present, and Future

Volumen 27, Ausgabe 3, 2010, pp. 187-236
DOI: 10.1615/CritRevTherDrugCarrierSyst.v27.i3.10
Get accessGet access

ABSTRAKT

The objective of this article is to provide the reader with an update on some research highlights from the past to the present, as well as future possibilities to achieve improved delivery of drugs across the blood–brain barrier (BBB). In the past, dye studies confirmed the presence of the BBB and blood–cerebrospinal fluid barriers, which seem to play a major role in transporting drug molecules for the treatment of life-threatening diseases such as brain cancer and Alzheimer's. Presently, transportation mechanisms such as simple diffusion, carrier-mediated, absorptive-mediated, and receptor-mediated transcytosis are extensively used for BBB uptake of drug molecules. The spectrum of future neuropharmaceuticals falling into these categories ranges from peptides to nucleotide-based drugs as well as gene and stem cell deli very agents, and is increasing at a rapid rate with promising results. There has also been considerable progress in the development of quantitative methods to examine BBB permeability in humans and animals. Currently, intravenous administration and in situ brain perfusion techniques are the most versatile and sensitive methods to measure transport into the brain. This article also reviews the various methodologies available for assessing the transfer of drug molecules undergoing significant uptake through the BBB in vivo.

REFERENZIERT VON
  1. Daneman Richard, The blood-brain barrier in health and disease, Annals of Neurology, 72, 5, 2012. Crossref

  2. Davies Michael A., Targeted Therapy for Brain Metastases, in Current Challenges in Personalized Cancer Medicine, 65, 2012. Crossref

  3. Siegal T., Which drug or drug delivery system can change clinical practice for brain tumor therapy?, Neuro-Oncology, 15, 6, 2013. Crossref

  4. Jain Aviral, Singhai Priyanka, Gurnany Ekta, Updhayay Satish, Mody Nishi, Transferrin-tailored solid lipid nanoparticles as vectors for site-specific delivery of temozolomide to brain, Journal of Nanoparticle Research, 15, 3, 2013. Crossref

  5. Chun Hyun Bae, Scott Michael, Niessen Sherry, Hoover Heather, Baird Andrew, Yates John, Torbett Bruce E, Eliceiri Brian P, The Proteome of Mouse Brain Microvessel Membranes and Basal Lamina, Journal of Cerebral Blood Flow & Metabolism, 31, 12, 2011. Crossref

  6. Neves Vera, Aires-da-Silva Frederico, Corte-Real Sofia, Castanho Miguel A.R.B., Antibody Approaches To Treat Brain Diseases, Trends in Biotechnology, 34, 1, 2016. Crossref

  7. Nicolas Jean-Marie, Species Differences and Impact of Disease State on BBB, in Blood-Brain Barrier in Drug Discovery, 2015. Crossref

  8. Liguori Lavinia, Pastorino Fabio, Rousset Xavier, Alfano Silvia, Cortes Sandra, Emionite Laura, Daga Antonio, Ponzoni Mirco, Lenormand Jean-Luc, Anti-Tumor Effects of Bak-Proteoliposomes against Glioblastoma, Molecules, 20, 9, 2015. Crossref

  9. Jain Aviral, Chasoo Gousia, Singh Shashank K., Saxena Ajit K., Jain Sanjay K., Transferrin-appended PEGylated nanoparticles for temozolomide delivery to brain:in vitrocharacterisation, Journal of Microencapsulation, 28, 1, 2011. Crossref

  10. Daneman Richard, Engelhardt Britta, Brain barriers in health and disease, Neurobiology of Disease, 107, 2017. Crossref

  11. de Luca Emanuela, Marinaro Federica, Niola Francesco, Tonelli Davide De Pietri, Cutting Edge Approaches for the Identification and the Functional Investigation of miRNAs in Brain Science, in Handbook of Neurobehavioral Genetics and Phenotyping, 2017. Crossref

  12. Guerra M., Blázquez J. L., Rodríguez E. M., Blood–brain barrier and foetal-onset hydrocephalus, with a view on potential novel treatments beyond managing CSF flow, Fluids and Barriers of the CNS, 14, 1, 2017. Crossref

  13. Pohl-Guimarães Fernanda, Yang Changlin, Dyson Kyle A., Wildes Tyler J., Drake Jeffrey, Huang Jianping, Flores Catherine, Sayour Elias J., Mitchell Duane A., RNA-Modified T Cells Mediate Effective Delivery of Immunomodulatory Cytokines to Brain Tumors, Molecular Therapy, 27, 4, 2019. Crossref

  14. Antimisiaris Sophia, Mourtas Spyridon, Papadia Konstantina, Brain targeting with lipidic nanocarriers, in Design of Nanostructures for Versatile Therapeutic Applications, 2018. Crossref

  15. Agrawal Mukta, Saraf Swarnlata, Saraf Shailendra, Antimisiaris Sophia G., Hamano Nobuhito, Li Shyh-Dar, Chougule Mahavir, Shoyele Sunday A., Gupta Umesh, Ajazuddin , Alexander Amit, Recent advancements in the field of nanotechnology for the delivery of anti-Alzheimer drug in the brain region, Expert Opinion on Drug Delivery, 15, 6, 2018. Crossref

  16. Siegal Tali, Which Drug or Drug Delivery Method Can Change Clinical Practice for Brain Tumor Therapy?, in Drug Delivery to the Brain, 10, 2014. Crossref

  17. Pandey Vikas, Gadeval Anuradha, Asati Saket, Jain Priyanka, Jain Navneet, Roy Ram Kumar, Tekade Muktika, Soni Vandana, Tekade Rakesh K., Formulation strategies for nose-to-brain delivery of therapeutic molecules, in Drug Delivery Systems, 2020. Crossref

  18. Yasaswi P. Soma, Shetty Karishma, Yadav Khushwant S., Temozolomide nano enabled medicine: promises made by the nanocarriers in glioblastoma therapy, Journal of Controlled Release, 336, 2021. Crossref

  19. Bussy Cyrill, Al-Jamal Khuloud T., Boczkowski Jorge, Lanone Sophie, Prato Maurizio, Bianco Alberto, Kostarelos Kostas, Microglia Determine Brain Region-Specific Neurotoxic Responses to Chemically Functionalized Carbon Nanotubes, ACS Nano, 9, 8, 2015. Crossref

  20. Russell-Jones Gregory, Intestinal receptor targeting for peptide delivery: an expert’s personal perspective on reasons for failure and new opportunities, Therapeutic Delivery, 2, 12, 2011. Crossref

  21. Aguiar Sandra Isabel, Dias Joana N. R., André Ana Santos, Silva Marta Lisete, Martins Diana, Carrapiço Belmira, Castanho Miguel, Carriço João, Cavaco Marco, Gaspar Maria Manuela, Nobre Rui Jorge, Pereira de Almeida Luís, Oliveira Soraia, Gano Lurdes, Correia João D. G., Barbas Carlos, Gonçalves João, Neves Vera, Aires-da-Silva Frederico, Highly Specific Blood-Brain Barrier Transmigrating Single-Domain Antibodies Selected by an In Vivo Phage Display Screening, Pharmaceutics, 13, 10, 2021. Crossref

  22. Petrenko Daria, Chubarev Vladimir, Syzrantsev Nikita, Ismail Nafeeza, Merkulov Vadim, Sologova Susanna, Grigorevskikh Ekaterina, Smolyarchuk Elena, Alyautdin Renad, Temozolomide Efficacy and Metabolism: The Implicit Relevance of Nanoscale Delivery Systems, Molecules, 27, 11, 2022. Crossref

  23. Desai Harita R., Shinde Ujwala A., Hybrid nanoparticles to cross the blood–brain barrier, in Nanocarriers for Drug-Targeting Brain Tumors, 2022. Crossref

  24. Zhang Yunhan, Zou Zhulin, Liu Shuang, Miao Shengjie, Liu Haiyan, Nanogels as Novel Nanocarrier Systems for Efficient Delivery of CNS Therapeutics, Frontiers in Bioengineering and Biotechnology, 10, 2022. Crossref

  25. Bartusik-Aebisher Dorota, Żołyniak Aleksandra, Barnaś Edyta, Machorowska-Pieniążek Agnieszka, Oleś Piotr, Kawczyk-Krupka Aleksandra, Aebisher David, The Use of Photodynamic Therapy in the Treatment of Brain Tumors—A Review of the Literature, Molecules, 27, 20, 2022. Crossref

Digitales Portal Digitale Bibliothek eBooks Zeitschriften Referenzen und Berichte Forschungssammlungen Preise und Aborichtlinien Begell House Kontakt Language English 中文 Русский Português German French Spain